News

This episode of Pharma Pulse covers the former CDC director’s claim she was dismissed for refusing to prioritize ideology over evidence, new findings that physician mental health remains a serious concern, and Eli Lilly’s $5 billion investment in a new Virginia manufacturing plant to expand biologics production.

In the final part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, shares how the value in ensuring patients and clinicians have access to accurate resources requires meeting them where they already seek information, with seamless, trustworthy education integrated into their daily workflows.

The new Goochland County facility will serve as Lilly’s first fully integrated API and drug product site, focusing on antibody-drug conjugates, while creating thousands of jobs and strengthening domestic supply chains.

This episode of Pharma Pulse covers new data showing 1 in 6 US parents are delaying or skipping childhood vaccinations, Secretary Robert F. Kennedy Jr.’s move to expand a federal vaccine advisory committee, and survey findings that more than half of healthcare workers are considering leaving their current roles.

In the third part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, notes that in a crowded weight management landscape, marketers play a critical role in combating misinformation by ensuring healthcare providers and patients have clear, accurate information on the safety, efficacy, and access pathways of FDA-approved treatments.

A new JAMA Network Open study highlights how over-the-counter oral contraceptives can reduce barriers to care, especially for uninsured, rural, and adolescent populations, amid shifting federal policies on reproductive health.

In the second part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, points out that as patient fatigue grows with injectable therapies, oral alternatives are emerging as vital tools for clinicians and patients alike, expanding choice, improving access, and supporting more personalized obesity treatment strategies.

The collaboration seeks to reduce drug waste, prevent errors, and support more reliable delivery of life-saving therapies to patients worldwide.

In the first part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, explains how predictable, affordable pricing models for FDA-approved oral weight loss drugs can reduce barriers to care, improve long-term adherence, and support better outcomes for patients managing chronic obesity.

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

In the final part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, details how in a post-COVID landscape, technologies that track and regionalize hospital inventory could become critical tools for state and local health departments, ensuring visibility, preparedness, and smarter resource allocation during future disruptions.

The South Korean CDMO has signed its second multi-billion-dollar contract in less than a year, even as shifting US trade policies and looming tariffs create challenges for global drugmakers.

Key points from our recent webinar on the President’s MFN order.

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for broader coverage and policy solutions.

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

In the third part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, explains why forward-thinking facilities see these tools as key to cutting errors and improving inventory efficiency.

The move consolidates R&D, manufacturing, and commercialization under the CGM system’s developer to accelerate growth and expand global reach.

This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.

In the second part of her Pharma Commerce video interview, Annika Matas, Zebra Technologies’ senior director of product management and business operations, supplies & sensors, shares that from automated RFID cabinets to handheld scanners, hospitals are streamlining inventory tracking, cutting labor costs, and reducing medication loss, especially critical during drug shortages.

By reducing waste, improving forecasting, and strengthening payer negotiations, these technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

In the first part of their Pharma Commerce video interview, Boyede Sobitan and Annika Matas of Zebra Technologies warn that ongoing medication shortages are forcing staff to borrow supplies, delay procedures, and divert nurses from patient care to logistical tasks, creating both financial pressures and operational inefficiencies.

The new 180,000-square-foot facility in Foster City anchors the company’s long-term $32 billion investment in domestic manufacturing and R&D.

In the final part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, focuses on physician demand, global momentum, and how US legislation can help the industry finally move beyond paper.

Following a federal appeals court decision that struck down much of his tariff authority under the International Emergency Economic Powers Act, President Trump is asking the Supreme Court to fast-track review.

In the second part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, highlights that cutting down on the 90 billion sheets of paper used for medicine inserts each year isn’t just an environmental win—it’s also a critical step toward making drug information more accessible for patients with vision challenges, language barriers, or cognitive and physical disabilities.

The company is committing over half a billion dollars to build a state-of-the-art research hub in Thousand Oaks, CA, designed to accelerate next-generation therapeutics through advanced automation and collaboration.

This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.